GSK Plc announced on October 29 that it acquired Syndivia‘s preclinical antibody-drug conjugate (ADC). Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific […]
The post GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
